CalciMedica, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
CALC$1.37-9.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Gain (Loss) | Equity | |
| Balance—December 31, 2024 | 13,481,917 | $4 | $174,166 | $(159,764) | $4 | $14,410 |
| Stock-based compensation expense | — | — | 549 | — | — | 549 |
| Issuance of common shares from underwritten public offering (net of issuance costs) | — | — | 8 | — | — | 8 |
| Issuance of common stock from at-the-market offering (net of issuance costs) | 490,073 | — | 968 | — | — | 968 |
| Unrealized loss on investments | — | — | — | — | (5) | (5) |
| Net loss | — | — | — | (5,042) | — | (5,042) |
| Balance—March 31, 2025 | 13,971,990 | 4 | 175,691 | (164,806) | (1) | 10,888 |
| Stock-based compensation expense | — | — | 1,174 | — | — | 1,174 |
| Unrealized loss on investments | — | — | — | — | (3) | (3) |
| Net loss | — | — | — | (5,956) | — | (5,956) |
| Balance—June 30, 2025 | 13,971,990 | $4 | $176,865 | $(170,762) | $(4) | $6,103 |
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Gain (Loss) | Equity | |
| Balance—December 31, 2023 | 5,754,505 | $1 | $154,218 | $(146,064) | $2 | $8,157 |
| Stock-based compensation expense | — | — | 414 | — | — | 414 |
| Issuance of common shares from private placement (net of issuance costs) | 4,985,610 | 2 | 7,903 | — | — | 7,905 |
| Issuance of warrants in connection with the private placement | — | — | 660 | — | — | 660 |
| Unrealized loss on investments | — | — | — | — | (19) | (19) |
| Net income | — | — | — | 130 | — | 130 |
| Balance—March 31, 2024 | 10,740,115 | $3 | $163,195 | $(145,934) | $(17) | $17,247 |
| Stock-based compensation expense | — | — | 486 | — | — | 486 |
| Issuance of common stock from at-the-market offering (net of issuance costs) | 8,950 | — | 47 | — | — | 47 |
| Issuance of common stock from exercise of stock options | 1,091 | — | 4 | — | — | 4 |
| Unrealized gain on investments | — | — | — | — | 8 | 8 |
| Net loss | — | — | — | (3,954) | — | (3,954) |
| Balance—June 30, 2024 | 10,750,156 | $3 | $163,732 | $(149,888) | $(9) | $13,838 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.